France’s temporary authorisation (ATU) programme: reform implications
The temporary authorisation for use (Autorisation Temporaire d’Utilisation, ATU) programme in France is intended to provide early access to medicines for...
With new technologies driving step changes in biopharma, we can help you predict and plan for the next round of disruptive changes.
Engagements
- 01Estimating economic damages relating to type 2 diabetes drugA pharmaceutical company brought on Christopher Gerardi to estimate economic damages arising from alleged infringement and at-risk launch of a patented oral...View engagement